Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Abstract

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.

• Authors: Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner, Marc S Ernstoff
• Journal: Journal for immunotherapy of cancer (J Immunother Cancer) Vol. 9 Issue 6 (06 2021) ISSN: 2051-1426 [Electronic] England
• PMID: 34172516 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Guidelines as Topic (standards)
• Humans
• Immune Checkpoint Inhibitors (adverse effects)
• Immunotherapy (methods)
• Neoplasms (drug therapy, immunology)
• Societies, Medical (standards)